Model Medicines Featured in C&EN's Coverage of Next-Generation COVID-19 Antivirals

Model Medicines was recently featured in Chemical & Engineering News (C&EN) in an article exploring the development of next-generation COVID-19 antivirals. The article, titled "The next generation of COVID-19 antivirals," highlights our innovative approach to drug discovery and our promising compound MDL-001.

Through our pioneering use of machine learning and artificial intelligence, Model Medicines has identified MDL-001 as a potential once-daily treatment for COVID-19. The compound has already demonstrated safety in a previous Phase 1 trial and has garnered attention from the U.S. National Institutes of Health's Antiviral Program for Pandemics, accelerating our path toward clinical development.

"We wanted a drug that potentially was so safe and well tolerated that it can be dosed to any patient groups regardless of variant, regardless of sex, regardless of age, regardless of comorbidities," our CEO Daniel Haders explained in the article.

The C&EN feature positions Model Medicines among several innovative companies working to develop improved treatments for COVID-19, highlighting our unique approach to drug repurposing through advanced computational methods.

Dr. Davey Smith, chief of infectious diseases and global health at the University of California San Diego and a clinical adviser for Model Medicines, provided additional context in the article about the evolving nature of the pandemic and the continued need for effective treatments: "I think COVID is going to be around for the rest of my career. We'll want to develop more tolerable, easier-to-get drugs along the way."